Thông tin thuốc gốc
Chỉ định và Liều dùng
Angina pectoris, Hypertension
Adult: Initially, 5 mg once daily adjusted according to response. Usual dose: 10 mg once daily. Max: 20 mg daily.

Chronic heart failure
Adult: Initially, 1.25 mg once daily. May be doubled after 1 week if tolerated, then gradually increase at 1-4 week intervals. Max: 10 mg once daily.
Special Patient Group
Patients with bronchospastic disease: Initially, 2.5 mg once daily.
Renal Impairment
Angina pectoris, Hypertension:
CrCl Dosage
<40 Initially, 2.5 mg once daily. Max: 10 mg daily.
Hepatic Impairment
Angina pectoris, Hypertension: Severe: Initially, 2.5 mg once daily. Max: 10 mg daily.
Cách dùng
May be taken with or without food.
Chống chỉ định
Cardiogenic and hypovolaemic shock, 2nd or 3rd degree atrioventricular block, sinoatrial block, sick sinus syndrome, symptomatic bradycardia and hypotension, untreated phaeochromocytoma, metabolic acidosis, severe peripheral arterial occlusive disease, severe Raynaud’s syndrome, severe bronchial asthma or severe COPD, acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy.
Thận trọng
Patient with bronchospastic disease, myasthenia gravis, Raynaud’s syndrome, diabetes mellitus, Prinzmetal’s angina, 1st degree atrioventricular block, peripheral arterial occlusive disease, psoriasis, hyperthyroidism, hypoglycaemia. Patients undergoing major surgery involving general anaesthesia. Avoid abrupt withdrawal. Renal and hepatic impairment. Pregnancy and lactation.
Phản ứng phụ
Blood and lymphatic system disorders: Agranulocytosis, thrombocytopenia.
Cardiac disorders: Chest pain, bradycardia, palpitations.
Eye disorders: Ocular pain, visual disturbance.
Gastrointestinal disorders: Vomiting, constipation, diarrhoea, dry mouth, abdominal pain.
General disorders and admin site conditions: Asthenia, fatigue.
Musculoskeletal and connective tissue disorders: Gout, back pain, arthralgia.
Nervous system disorders: Dizziness, headache.
Respiratory, thoracic and mediastinal disorders: Dyspnoea, rhinitis, sinusitis.
Skin and subcutaneous tissue disorders: Rash, eczema, pruritus. Rarely, alopecia.
Vascular disorders: Syncope, cold or numb extremities, hypotension, flushing.
Monitoring Parameters
Monitor ECG, heart rate and blood pressure.
Quá liều
Symptoms: Bradycardia, hypotension, bronchospasm, and hypoglycaemia. Management: Symptomatic and supportive treatment. Administer IV atropine for bradycardia, if inadequate, isoproterenol may be given cautiously. IV fluids, vasopressors and IV glucagon should be administered for hypotension. Administer bronchodilator therapy (e.g. isoproterenol and/or aminophylline) for bronchospasm; and IV glucose for hypoglycaemia.
Tương tác
May potentiate atrioventricular conduction time and may increase negative inotropic effect with class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant use with calcium antagonists (e.g. verapamil, diltiazem) may lead to atrioventricular block and profound hypotension. Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive reduction of sympathetic activity. Heart failure may worsen when given with centrally acting antihypertensives (e.g. clonidine, methyldopa). Increased risk of bradycardia with digitalis glycosides. Coadministration with rifampicin increases metabolic clearance of bisoprolol. Reduced hypotensive effect with NSAIDs.
Lab Interference
May result to false-positive aldosterone/renin ratio (ARR).
Tác dụng
Description: Bisoprolol selectively and competitively blocks β1-adrenergic receptors but has little or no effect on β2-receptors except at high doses (≥20 mg).
Onset: 1-2 hours.
Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract. Absolute oral bioavailability: Approx 80-90%. Time to peak plasma concentration: 2-4 hours.
Distribution: Widely distributed with highest concentrations in heart, liver, lungs, and saliva. Crosses blood-brain barrier. Volume of distribution: 3.5 L/kg. Plasma protein binding: Approx 30-35%.
Metabolism: Extensively metabolised in the liver mainly via oxidation by CYP3A4 (approx 95%) and CYP2D6 enzymes. Undergoes significant first-pass metabolism (approx 10-20%).
Excretion: Via urine (approx 50% as unchanged drug and 50% as inactive metabolites) and via faeces (<2%). Elimination half-life: 9-12 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Bisoprolol, CID=2405, (accessed on Jan. 21, 2020)

Bảo quản
Store between 20-25°C. Protect from light and moisture.
Phân loại MIMS
Phân loại ATC
C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Anon. Bisoprolol Fumarate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 08/02/2019.

Anon. Bisoprolol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 08/02/2019.

Bisoprolol Fumarate (Aurobindo Pharma Ltd). DailyMed. Source: U.S. National Library of Medicine. Accessed 08/02/2019.

Buckingham R (ed). Bisoprolol Fumarate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 08/02/2019.

Joint Formulary Committee. Bisoprolol Fumarate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 08/02/2019.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Bisoprolol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Agicardi
  • Bihasal
  • Bio-Biso 5
  • Biprolol
  • Biscapro 2.5/5
  • Biselect
  • Bisohexal
  • Bisolcor
  • Bisoloc
  • Bisoprolol OPV
  • Bisostad
  • Bisotab
  • Cardicormekophar
  • Concor
  • Concor COR
  • Domecor
  • Glocor
  • Haiblok
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in